A bone overgrowth disorder due to a gain-of-function mutation in the kinase homology domain of guanylyl cyclase B, the receptor for CNP by unknown
POSTER PRESENTATION Open Access
A bone overgrowth disorder due to a gain-of-
function mutation in the kinase homology domain
of guanylyl cyclase B, the receptor for CNP
Michaela Kuhn1*, Thomas Premsler1, Ruey-Bing Yang2, Thomas D Mueller3, Birgit Gaßner1, Heike Oberwinkler1,
Sabine E Hannema4, Hermine A van Duyvenvoorde4, Ferdinand Roelfsema5, Gijs WE Santen6, Timothy Prickett7,
Sarina G Kant6, Annemieke JMH Verkerk8, André G Uitterlinden8, Eric Espiner7, Claudia AL Ruivenkamp6,
Wilma Oostdijk4, Alberto M Pereira5, Monique Losekoot6, Jan M Wit4
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
C-type natriuretic peptide (CNP), via its guanylyl cyclase
B (GC-B) receptor and intracellular cGMP, is critically
involved in bone development by regulating growth
plate chondrocyte differentiation and proliferation.
Homozygous loss-of-function mutations in GC-B lead to
short-limbed dwarfism (acromesomelic dysplasia, type
Maroteaux). Here we describe a novel heterozygous
gain-of-function mutation in an extremely tall patient
displaying mild scoliosis and a non-Marfanoid habitus.
Materials and methods
Whole exome sequencing revealed a heterozygous GC-B
mutation resulting in a single amino acid exchange
within the submembrane kinase homology domain
(KHD). The impact on cGMP formation was studied in
transfected HEK293 cells and in cultured fibroblasts
obtained from the patient and healthy donors. The inter-
action of wildtype and mutated GC-B was evaluated by
co-immunoprecipitation.
Results
Basal and CNP-stimulated cGMP syntheses by homozy-
gous and heterozygous mutant GC-B dimers were mark-
edly increased in HEK293 cells and in patient skin
fibroblasts. Homology modeling revealed that the mutation
is adjacent to the ATP-binding pocket of the KHD domain.
Notably, ATP potentiated CNP effects on wildtype and
much more on mutated GC-B. Finally, co-IP demonstrated
that wildtype und mutant GC-B form heterodimers,
explaining the functional impact of this point mutation on
receptor activity under (human) heterozygous conditions.
Conclusion
Our study unravels for the first time a point mutation in
the KHD of GC-B which dramatically enhances cGMP
production by the adjacent GC domain. This remarks the
regulatory role of the KHD and suggests that configuration
of the ATP-binding pocket provides a critical allosteric
regulatory step in CNP/GC-B signal transduction.
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